Copy Link Print Information

LY2109761

71 Cited Publications
カスタマーレビュー

Based on 71 publication(s) in Google Scholar

LY2109761 is an orally active, selective TGF-β receptor type I/II inhibitor with Kis of 38 nM and 300 nM, respectively.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

  • 純度: 99.72%
  • CAS 番号: 700874-71-1
  • 分子式: C26H27N5O2
  • 分子量:441.52
  • 保管条件:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 1 year , -20°C, 6 months
  • LY2109761 Chemical Structure
    LY2109761 構造式
  • Experimental Validation Results for LY2109761
  • Experimental Validation Results for LY2109761
  • Experimental Validation Results for LY2109761
  • Experimental Validation Results for LY2109761
  • Experimental Validation Results for LY2109761
CAS 番号: 700874-71-1
容量
価格（税別）
在庫状況
数量
Amount: USD 0.00
Please select quantity
or
or

* アイテムを追加する前、数量をご選択ください

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of LY2109761:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
最寄りの代理店をお探しください Your local distributor: Hycultec GmbHHycultec
  • 生物活性
  • 化学情報
  • 溶剤 & 溶解度
  • プロトコル
  • 純度とドキュメンテーション
  • 参考文献
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

MedChemExpress（MCE）の使用を引用している文献 LY2109761

More
Customer Validation & Images
WB
  • WB
  • WB
  • WB
  • WB
  • WB

TGF-β Receptor アイソフォーム固有の製品をすべて表示

More
Keywords
100 mg

お問い合わせ 在庫あり

Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress ログイン
Register
Sign in to MedChemExpress
新規会員登録

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • LY2109761 Chemical Structure
    LY2109761 Chemical Structure
    1/16
  • 1/16

    LY2109761 purchased from MedChemExpress. Usage Cited in: Biochim Biophys Acta Mol Basis Dis. 2018 Nov;1864(11):3824-3836. [Abstract]

    Customer Validation
     LY2109761 at 100 nM, 10 μM, or 50 μM is added for 30 min to block TGFβR1/2 prior to TGF-β1-treatment, then proteins are collected, and the levels of Sphk2, fibronectin, and α-SMA are detected by Western blotting.

  • 1/16

    LY2109761 purchased from MedChemExpress. Usage Cited in: Mol Immunol. 2018 Nov:103:173-181. [Abstract]

    Customer Validation
     TRPM7 mRNA and protein expressions are effectively suppressed by LY2109761 and SIS3 in ASMCs compared with those in 10 ng/mL TGF-β1-stimulated cells.

  • 1/16

    LY2109761 purchased from MedChemExpress. Usage Cited in: Cell Biol Int. 2017 Sep;41(9):960-968. [Abstract]

    Customer Validation
     The phosphorylation level of Smad2 is significantly inhibited by LY2109761. The M2 macrophage-induced increase of α-SMA and decrease of E-cadherin and CK-18 are inhibited by LY2109761.

  • 1/16

    LY2109761 purchased from MedChemExpress. Usage Cited in: J Hepatol. 2015 Oct;63(4):863-73. [Abstract]

    Customer Validation
     Blocking the TGF-beta and ERK signalling effectively inhibits EDIL3 mediated angiogenesis and invasion. Western blotting analysis of the expression of p-ERK and p-Smad2 in DMSO- and VX-11e or LY2109761-treated HuH7-p-lenti-EDIL3 cells. GAPDH is used as a loading control.

  • 1/16

    LY2109761 purchased from MedChemExpress. Usage Cited in: Int J Mol Med. 2015 Jun;35(6):1667-74. [Abstract]

    Customer Validation
     Inhibition of the TGF-β1/Smad2 pathway decreases H2O2-induced human umbilical vein endothelial cell (HUVEC) apoptosis, but not oxidative stress. Western blot analysis is performed to determine protein expression in the HUVECs in the control, model, AST Ⅳ and LY2109761 groups.

  • LY2109761